Vnitr Lek 2005, 51(11):1297-1302

Type 1A diabetes mellitus and autoimmunity

D. Vrlíková*, M. Mokáň
I. interná klinika Jesseniovej lekárskej fakulty UK a Martinskej FN, Martin, Slovenská republika, prednosta prof. MUDr. Marián Mokáň, DrSc.

Type 1A diabetes mellitus presents the most frequent part of type 1 DM. This disease is caused by an autoimmune destruction of pancreatic β-cells. Genetic, autoimmune and environmental factors are responsible for the development of type 1 diabetes. The most important genes that determinate the development of the disease are genes of Major Histocompatibility Complex (MHC). There is evidence that viral infection acts as a triggering event of autoimmune reaction. The immune response to a microbial determinant would cross-react with host tissues and results in an activation and proliferation of T-lymphocytes that cause destruction of pancreatic β-cells.

Keywords: type 1A diabetes mellitus; HLA-alleles; T-lymphocytes; pancreatic β-cells

Received: January 14, 2005; Accepted: April 20, 2005; Published: November 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrlíková D, Mokáň M. Type 1A diabetes mellitus and autoimmunity. Vnitr Lek. 2005;51(11):1297-1302.
Download citation

References

  1. Acton RT. The major histocompatibility complex. In: Rich RR (ed). Clinical Imunolgy, Principles and Practice. London, Edinburg, New York, Philadelphia, St. Louis, Sydney, Toronto: Mosby 2001: 6.1-6.13.
  2. Buc M. Klinická imunológia. Bratislava: Veda 1997.
  3. Buc M. Imunológia. Bratislava: Veda 2001.
  4. Buc M, Shawkatová I. Imunopatogenéza diabetes mellitus 1A. J Čes Slov pediatria 2002; 57: 299-305.
  5. Černá M, Žďárský E, Anděl M. HLA-systém a diabetes mellitus 1. typu. J DMEV 2000; 2: 8-15.
  6. Devendra D, Liu E, Eisenbarth GS. Type 1 Diabetes: recent developments. Brit Med J 2004; 328: 750-754. Go to original source... Go to PubMed...
  7. Fourlanos S, Dotta F, Greenbaum CJ et al. Latent autoimmune diabetes in adults (LADA) making it less latent. Autoimmunity 1999; 29: 65-83.
  8. Hagopian WA, Sanjevi CB, Kockum I et al. Glutamate decarboxylase, insulin, islet cell autoantibodies and HLA typing to detect diabetes in a general population - based study of Swedish children. J Clin Invest 1995; 95: 1505-1511. Go to original source... Go to PubMed...
  9. Larsen CE, Alper CA. The genetics of HLA-associated disease. J Curr Opin Imunol 2004; 5: 660-667. Go to original source... Go to PubMed...
  10. Leslie D, Valeri C. Latent autoimmune diabetes in adults (LADA). Diabetes Voice 2003; 48: 14-16.
  11. Mokáň M. Diabetes mellitus. In: Ďuriš I, Hulín I, Bernadič M (eds). Princípy internej medicíny. Bratislava: SAP 2001: 2152-2182.
  12. Mokáň M. Diabetes mellitus. In: Šašinka M, Nyulassy Š, Badalík L (eds). Vademecum medici. Martin: Osveta 2003: 959-982.
  13. Novák J, Anděl M. Buněčná imunita v patogenezi diabtes mellitus 1. typu. J DMEV 2001; 4: 7-11.
  14. Palmer JP, Hirsch IB What's in a name: Latent autoimmune diabetes of adults, type 1,5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26: 536-538. Go to original source... Go to PubMed...
  15. Pugliese A. Genetics of type 1 diabetes. Endocrinal Metab Clin North Am, 2004; 33: 1-16. Go to original source... Go to PubMed...
  16. Robles DT, Eisenbath GS. Diabetes and related autoimunne diseases. In: Rich RR (ed). Clinical Imunology, Principles and Practice. London, Edinburg, New York, Philadelphia, St.Louis, Sydney, Toronto: Mosby 2001: 82.1-82.18.
  17. Stites DP, Terr AI. Základní a klinická imunologie. Praha: Victoria Publishing 1994.
  18. Turský T, Banduchová E. Dekarboxyláza glutamátu - autoantigén pri inzulín-dependentnom diabetes mellitus. J Bratislav Lek Listy 1999; 100: 85-88.
  19. Vandewalle ChL, Falorni A, Svanholm S et al. High diagnostic sensitivity glutamate decarboxylase autoantibodies in insulin dependent diabetes mellitus with clinical onset between age 20-40 years. J Clin Invest 1996; 98: 2597-2603. Go to original source...
  20. Virella G, Goust JM. Organ-specific autoimunne diseases. In: Virella G. (ed). Medical imunology. New York, Basel: Marcel Dekker 2001: 341-376. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.